Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2013 Available from: http://www.goldcopd.orgAccessed Dec 2012
   Google Scholar
• BarnesPJCelliBRSystemic manifestations and comorbidities of COPDEur Respir J20093351165118519407051
   PubMed Web of Science ®Google Scholar
• DecramerMRennardSTroostersTCOPD as a lung disease with systemic consequences – clinical impact, mechanisms, and potential for early interventionCOPD20085423525618671149
   PubMedGoogle Scholar
• AgustiASorianoJBCOPD as a systemic diseaseCOPD20085213313818415812
   PubMedGoogle Scholar
• FabbriLMLuppiFBeghéBRabeKFComplex chronic comorbidities of COPDEur Respir J200831120421218166598
   PubMed Web of Science ®Google Scholar
• van EedenSFSinDDChronic obstructive pulmonary disease: a chronic systemic inflammatory diseaseRespiration200875222423818042978
   PubMed Web of Science ®Google Scholar
• MidgleyTJrHeeneALOrganic fluorides as refrigerantsInd Eng Chem1937225542545
   Google Scholar
• ZhongWHistory of CFCs as refrigerants Accessed http://zwhudson.myweb.uga.edu/chem8290/replacement%20of%20CFCs%20as%20refrigerants.htmAccessed March 11, 2013
   Google Scholar
• TsaiWTAn overview of environmental hazards and exposure risk of hydrofluorocarbons (HFCs)Chemosphere200561111539154715936055
   PubMed Web of Science ®Google Scholar
• LovelockJEAtmospheric fluorine compounds as indicators of air movementsNature1971230379
   Web of Science ®Google Scholar
• LeachCLThe CFC to HFA Transition and its impact on pulmonary drug developmentRespir Care20055091201120616122403
   PubMedGoogle Scholar
• RowlandFSStratospheric ozone depletionPhilos Trans R Soc Lond B Biol Sci2006361146976979016627294
   PubMed Web of Science ®Google Scholar
• FarmanJSGardinerBGShanklinJDLarge losses of total ozone in Antarctic reveal seasonal ClOx/NOx interactionNature1985315207210
   Web of Science ®Google Scholar
• KerrRAAnother deep Antarctic ozone holeScience1990250497937017793009
   PubMed Web of Science ®Google Scholar
• Ozone hole through the years [web page on the Internet]Greenbelt, MDEarth Observatory2011 Available from: http://earthobservatory.nasa.gov/IOTD/view.php?id=49040Accessed Dec 2012
   Google Scholar
• MolinaMJRowlandFSStratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozoneNature1974249810814
   Web of Science ®Google Scholar
• ButtATKamatDPansareMFinal count down to hfa albuterol inhalers: are we ready as yet?Clin Pediatr (Phila)200948213113419015282
   PubMed Web of Science ®Google Scholar
• GribbenJThe Hole in the Sky: Man’s Threat to the Ozone LayerLondonCorgi1987
   Google Scholar
• RogersHWWeinstockMAHarrisARIncidence estimate of nonmelanoma skin cancer in the United States, 2006Arch Dermatol2010146328328720231499
   PubMed Web of Science ®Google Scholar
• KohHKGellerACMillerDRGrossbartTALewRAPrevention and early detection strategies for melanoma and skin cancer. Current statusArch Dermatol199613244364428629848
   PubMedGoogle Scholar
• ReedKBBrewerJDLohseCMBringeKEPruittCNGibsonLEIncreasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, MinnesotaMayo Clin Proc201287432833422469345
   PubMed Web of Science ®Google Scholar
• van der LeunJCTakizawaYLongstrethJDHuman healthUnited Nations Environment ProgrammeEnvironmental Effects Panel ReportNairobiUnited Nations Environment Programme19891124 Available from: http://www.ciesin.org/docs/001-538/001-538.htmlAccessed Dec 2012
   Google Scholar
• WoodcockAThe Montreal Protocol: getting over the finishing line?Lancet2009373966570570619249618
   PubMed Web of Science ®Google Scholar
• VeldersGJAndersenSODanielJSFaheyDWMcFarlandMThe importance of the Montreal Protocol in protecting climateProc Natl Acad Sci USA2007104124814481917360370
   PubMed Web of Science ®Google Scholar
• AndersonSOSarmaKMTaddonioKNBackground of the ozone and climate agreementsTechnology Transfer for the Ozone Layer: Lessons for Climate ChangeLondonEarthscan20072343
   Google Scholar
• ZeidlerMCorrenJHydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthmaTreat Respir Med200431354415174892
   PubMedGoogle Scholar
• DockhornRJWagnerDEBurgessGLProventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolinAnn Allergy Asthma Immunol199779185889236507
   PubMed Web of Science ®Google Scholar
• ClarkAThe physics of aerosol formation by MDIs: limitations of the current approachJ Biopharm Sci1992316976
   Google Scholar
• HarrisonEChange in the air. Banning CFC-driven inhalers could levy a toll on asthma sufferersSci Am200829922022
   Google Scholar
• NewmanSPPrinciples of metered-dose inhaler designRespir Care20055091177119016122401
   PubMedGoogle Scholar
• DalbyRNEicherJZierenbergBDevelopment of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disordersMed Devices (Auckl)2011414515522915941
   PubMedGoogle Scholar
• DalbyRSpallekMVoshaarTA review of the development of Respimat Soft Mist InhalerInt J Pharm20042831–21915363496
   PubMed Web of Science ®Google Scholar
• van NoordJASmeetsJJCreemersJPGreefhorstLPDewberryHCornelissenPJDelivery of fenoterol via Respimat, a novel ‘soft mist’ inhaler. A randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patientsRespiration200067667267811124651
   PubMed Web of Science ®Google Scholar
• LongestPWHindleMChoudhuriSDByronPRNumerical simulations of capillary aerosol generation: CFD model development and comparisons with experimental dataAerosol Sci Technol20074110952973
   Web of Science ®Google Scholar
• LongestPWHindleMChoudhuriSDXiJComparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth–throat geometryJ Aerosol Sci2008397572591
   Web of Science ®Google Scholar
• NewmanSPPaviaDMorénFSheahanNFClarkeSWDeposition of pressurised aerosols in the human respiratory tractThorax198136152557292382
   PubMed Web of Science ®Google Scholar
• NewmanSPAerosol deposition considerations in inhalation therapyChest198588Suppl 2152S160S3893925
   PubMed Web of Science ®Google Scholar
• SteinSWGabrioBJUnderstanding Throat Deposition During Cascade Impactor TestingRNDalbyPRByronSJFarrJPeartRespiratory Drug Delivery VIISerentecRaleigh, NC2000573576
   Google Scholar
• LongestPWHindleMQuantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow pathsJ Aerosol Med Pulm Drug Deliv200922327128319466904
   PubMed Web of Science ®Google Scholar
• HochrainerDHölzHKreherCScaffidiLSpallekMWachtelHComparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalersJ Aerosol Med200518327328216181002
   PubMedGoogle Scholar
• KhachikianDVA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist ExecutivesIpratropium/Albuterol (Combivent® Respimat®) Abbreviated Review2012 Available from: http://www.pbm.va.gov/ClinicalGuidance/AbbreviatedReviews/Ipratropium-albuterol(CombiventRespimat).docAccessed February 12, 2013
   Google Scholar
• NewmanSPSteedKPReaderSJHooperGZierenbergBEfficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizerJ Pharm Sci19968599609648877887
   PubMed Web of Science ®Google Scholar
• NewmanSPBrownJSteedKPReaderSJKladdersHLung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devicesChest199811349579639554631
   PubMed Web of Science ®Google Scholar
• PitcairnGReaderSPaviaDNewmanSDeposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhalerJ Aerosol Med200518326427216181001
   PubMedGoogle Scholar
• BrandPHedererBAustenGDewberryHMeyerTHigher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor techniqueInt J Chron Obstruct Pulmon Dis20083476377019281091
   PubMedGoogle Scholar
• Boehringer IngelheimFrequently asked questions about COMVIVENT RESPIMAT [web page on the Internet]IngelheimBoehringer Ingelheim Available from: http://www.combivent.com/respimat/faq.htmlAccessed Jan 2013
   Google Scholar
• ZuwallackRDe SalvoMCKaelinTCombivent Respimat Inhaler Study GroupEfficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDIRespir Med201010481179118820172704
   PubMed Web of Science ®Google Scholar
• KilfeatherSAPonitzHHBeckEImproved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPDRespir Med200498538739715139567
   PubMed Web of Science ®Google Scholar
• IaconoPVelicitatPGuemasELeclercVThébaultJJImproved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPDRespir Med200094549049510868713
   PubMed Web of Science ®Google Scholar
• RamFSCarvallhoCRWhiteJClinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devicesInt J Chron Obstruct Pulmon Dis2011612913921468167
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• HodderRReesePRSlatonTAsthma patients prefer Respimat Soft Mist Inhaler to TurbuhalerInt J Chron Obstruct Pulmon Dis2009422523219554196
   PubMedGoogle Scholar
• RamFSBrocklebankDMMuersMWrightJJonesPWPressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20021CD00217011869627
   PubMedGoogle Scholar
• BrocklebankDRamFWrightJComparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literatureHealth Technol Assess2001526114911701099
   PubMedGoogle Scholar
• DolovichMBAhrensRCHessDRAmerican College of Chest PhysiciansAmerican College of Asthma, Allergy, and ImmunologyDevice selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and ImmunologyChest2005127133537115654001
   PubMed Web of Science ®Google Scholar
• WelchMJNelsonHSShapiroGComparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler versus pressurized metered-dose inhalersJ Aerosol Med200417212913915294063
   PubMedGoogle Scholar
• KozmaCMSlatonTLMonzBUHodderRReesePRDevelopment and validation of a patient satisfaction and preference questionnaire for inhalation devicesTreat Respir Med200541415215725049
   PubMedGoogle Scholar
• MonzBKozmaCReesePSlatonTHodderRPatient Satisfaction and Preference Questionnaire (PASAPQ) User ManualBoehringer Ingelheim International GmbH2005 [email protected]
   Google Scholar
• HodderRPriceDPatient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhalerInt J Chron Obstruct Pulmon Dis2009438139019888356
   PubMedGoogle Scholar
• SchürmannWSchmidtmannSMoroniPMasseyDQidanMRespimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfactionTreat Respir Med200541536115725050
   PubMedGoogle Scholar
• SinghSLokeYKEnrightPFurbergCDPro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medicationsThorax201368111411622764216
   PubMed Web of Science ®Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
   PubMedGoogle Scholar
• DongYHLinHHShauWYChangCHLaiMSComparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trialsThorax2013681485623042705
   PubMed Web of Science ®Google Scholar
• JenkinsCRBeasleyRTiotropium Respimat increases the risk of mortalityThorax20136815723229813
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEEnrightPLManfredaJLung Health Study Research GroupHospitalizations and mortality in the Lung Health StudyAm J Respir Crit Care Med2002166333333912153966
   PubMed Web of Science ®Google Scholar
• MacieCWooldrageKManfredaJAnthonisenNCardiovascular morbidity and the use of inhaled bronchodilatorsInt J Chron Obstruct Pulmon Dis20083116316918488440
   PubMedGoogle Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535
   PubMed Web of Science ®Google Scholar
• OgaleSSLeeTAAuDHBoudreauDMSullivanSDCardiovascular events associated with ipratropium bromide in COPDChest20101371131919363211
   PubMed Web of Science ®Google Scholar
• WilcheskyMErnstPBrophyJMPlattRWSuissaSBronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohortChest2012142230531122871756
   PubMed Web of Science ®Google Scholar
• WangMTTsaiCLLoYWLiouJTLeeWJLaiICRisk of stroke associated with inhaled ipratropium bromide in chronic obstructive pulmonary disease: a population-based nested case-control studyInt J Cardiol2012158227928422386700
   PubMed Web of Science ®Google Scholar
• GordonJPanosRJInhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary diseaseExpert Opin Drug Metab Toxicol20106338139220163324
   PubMed Web of Science ®Google Scholar